Glucose Aguettant (Glucose Monohydrate)

Glucose Aguettant is an over‑the‑counter intravenous solution whose sole active ingredient is glucose monohydrate. It is supplied as a sterile liquid for parenteral administration, without a specified concentration, and is marketed within the European Union. As an excipient classified under ATC code B05BA01, it functions primarily as a carbohydrate source and osmotic agent in fluid‑replacement and electrolyte management as well as nutrition regimens.

Glucose Aguettant is used in clinical settings where rapid carbohydrate provision and fluid balance are required.

- Intravenous fluid and electrolyte replacement in patients unable to tolerate oral intake. - Component of parenteral nutrition formulas for short‑term or peri‑operative support. - Energy source during hypoglycaemia or metabolic stress. - Adjunct in resuscitation protocols to maintain intravascular volume. - Support for patients receiving dialysis or continuous renal replacement therapy.

Adverse reactions to Glucose Aguettant are generally related to its osmotic properties and the underlying clinical condition.

Common: - Mild hyperglycaemia. - Local irritation at the infusion site. - Transient electrolyte shifts (e.g., sodium, potassium). - Nausea or vomiting when administered rapidly.

Serious: - Severe hyperglycaemia requiring insulin therapy. - Fluid overload leading to pulmonary oedema. - Hyperosmolar hyperglycaemic state. - Allergic reaction such as urticaria or anaphylaxis.

When prescribing Glucose Aguettant, clinicians should evaluate patient‑specific factors and monitor relevant parameters.

- Assess blood glucose levels before and during infusion. - Monitor fluid balance and signs of overload, especially in cardiac or renal impairment. - Adjust dose in patients with diabetes mellitus or insulin resistance. - Use caution in neonates, infants, and the elderly due to altered metabolism. - Verify compatibility with other intravenous medications before co‑administration. - Ensure sterile technique to prevent infection.

Glucose Aguettant may interact with other agents administered intravenously or affect systemic metabolic pathways.

Avoid: - Co‑administration with high‑dose insulin without glucose monitoring, which can precipitate severe hypoglycaemia. - Simultaneous infusion of hypertonic solutions that could exacerbate osmotic shifts. - Use with medications that contain potassium or sodium in excess, risking electrolyte imbalance.

Use with caution: - Concurrent use of diuretics that alter fluid status. - Administration alongside vasopressors, as volume changes may affect hemodynamics. - Combination with other carbohydrate‑containing solutions, which may increase total caloric load. - Overlap with contrast agents, requiring monitoring of renal function.